We are aware of an issue causing the title of some ARTG entries to disappear. We are investigating as a priority and hope to have this resolved as soon as possible.
NERLYNX (Specialised Therapeutics PM Pty Ltd)
Product name
NERLYNX
Date registered
Evaluation commenced
Decision date
Approval time
200 working days (255)
Active ingredients
neratinib maleate
Registration type
NCE/NBE
Indication
NERLYNX (film coated tablets) is indicated for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy.